CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia

International Journal of Hematology

Volumn 93, Issue 6, 2011, Pages 779-781

  Muramatsu, Hideki ^a   Takahashi, Yoshiyuki ^a   Shimoyama, Yoshie ^b   Doisaki, Sayoko ^a   Nishio, Nobuhiro ^a   Ito, Yoshinori ^a   Hama, Asahito ^a   Shimada, Akira ^a   Yagasaki, Hiroshi ^a   Ito, Masafumi ^c   Kojima, Seiji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Aplastic anemia; CD20; Epstein Barr virus; Post transplant lymphoproliferative disease; Rituximab; Unrelated bone marrow transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN; METHOTREXATE; RITUXIMAB; TACROLIMUS;

APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE SEVERITY; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; POSITRON EMISSION TOMOGRAPHY; SCHOOL CHILD;

ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHILD; DNA COPY NUMBER VARIATIONS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; KIDNEY; LYMPHOPROLIFERATIVE DISORDERS; PHARYNX; POSITRON-EMISSION TOMOGRAPHY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79960079358     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-011-0870-3     Document Type: Article

References (8)

1. J Styczynski H Einsele L Gil P Ljungman 2009 Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases Transpl Infect Dis. 11 383 392
2. MR Smith 2003 Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene. 22 7359 7368
3. J Hiraga A Tomita T Sugimoto 2009 Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance Blood 113 4885 4893
4. EB Papadopoulos M Ladanyi D Emanuel 1994 Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation N Engl J Med 330 1185 1191 (Pubitemid 24121987)
5. I Kuehnle MH Huls Z Liu 2000 CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation Blood 95 1502 1505 (Pubitemid 30099868)
6. A Faye P Quartier Y Reguerre 2001 Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children Br J Haematol 115 112 118 (Pubitemid 32995103)
7. JW van Esser HG Niesters B van der Holt 2002 Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation Blood 99 4364 4369 (Pubitemid 34627202)
8. P Comoli S Basso M Zecca 2007 Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation Am J Transplant 7 1648 1655 (Pubitemid 46776261)